Biohaven Ltd. (NYSE: BHVN) experienced a sharp pullback in trading on Thursday, with shares declining 7.1% to $15.75 by 10:19 a.m. EDT. The drop erased 47% of the $2.57 surge recorded on Wednesday, when the company announced a $400 million licensing agreement for its epilepsy drug candidate opakalim. Despite the retreat, the stock remains 9.5% above its August 25 close of $14.38, suggesting that investors are still weighing the benefits of the cash infusion against the loss of future commercial potential.
The deal, struck with South Korea's SK Biopharmaceuticals, grants the latter an exclusive global license to Biohaven's Kv7 potassium channel platform, with opakalim as the lead asset. Under the terms, Biohaven will receive $350 million upon closing, followed by an additional $50 million after one year. The upfront payment represents roughly 14.7% of Biohaven's current market capitalization, which stands at approximately $2.38 billion based on Thursday's share price and 151.04 million shares outstanding.
Wednesday's trading activity was notably heavy, with 15.77 million shares changing hands—5.2 times the stock's 65-day average volume. That enthusiasm, however, has cooled in subsequent sessions. By Thursday morning, volume had reached just 962,594 shares, suggesting that the initial spike may have been driven by short-term speculation rather than long-term conviction.
The agreement also includes potential milestone payments of up to $150 million tied to development and regulatory achievements, as well as the assumption of up to $245 million in obligations from Knopp Biosciences by SK. Combined contingent payments could reach $795 million, or 33.4% of the company's valuation, though these amounts are not guaranteed and depend on clinical and commercial success.
For Biohaven, the deal provides a significant liquidity boost. As of June 30, the company held $270.5 million in cash, securities, and restricted cash. The $400 million in near-term consideration is equivalent to 1.48 times that figure, extending the company's cash runway and easing financial pressures as it continues to advance its pipeline.
However, the trade-off is substantial. Opakalim, currently in Phase 2/3 trials for focal epilepsy, was Biohaven's most advanced asset. By licensing it out, the company forfeits a large share of future upside, particularly if the drug succeeds in the clinic. RBC Capital Markets analyst Leonid Timashev described the deal as "fairly surprising," noting that the timing—just ahead of key data readouts—could explain Thursday's reversal.
Wall Street's reaction has been mixed. Of the analysts covering Biohaven, eleven rate the stock a Buy, one has an Overweight, three recommend Hold, and one suggests Underweight. The average price target stands at $22.07, implying a potential upside of 40.1% from current levels, while the lowest target of $10 suggests a downside risk of 36.5%.
The near-term focus now shifts to the RISE3 study, a Phase 2/3 trial of opakalim in focal epilepsy, with topline results expected in the second half of 2026. The outcome will be critical: positive data could unlock milestone payments and royalties, while a failure could eliminate the most significant contingent value in the agreement. Biohaven will also need to continue progressing the RISE2 trial and prepare regulatory submissions, as required by the deal.
For investors, the stock's movement reflects a classic risk-reward scenario. The deal provides immediate cash and reduces financial obligations, but it also caps the potential returns from opakalim. As the market digests this trade-off, the share price is likely to remain sensitive to clinical developments and the progress of the licensing agreement through antitrust review.
